Dividendos de Iovance Biotherapeutics

Dividendo controles de criterios 0/6

Iovance Biotherapeutics no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.8%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$1.61
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi

May 10

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Apr 09

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Mar 25

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Feb 20

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Jan 19

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Sep 27

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Aug 25

Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside

Mar 25

Iovance Biotherapeutics: Uncertainty And Opportunity

Dec 05

Iovanve Biotherapeutics (IOVA) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Jun 16

Iovance Bio reports 33-month follow up data for lifileucel in advanced melanoma at ASCO21

Jun 07

Iovance: Down And Rebound

May 30

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de IOVA han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de IOVA han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Iovance Biotherapeutics vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de IOVA con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (IOVA)	n/a
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.6%
Media de la industria (Biotechs)	2.8%
Previsión de analistas en 3 años (IOVA)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de IOVA en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de IOVA en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de IOVA para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que IOVA no ha comunicado ningún pago.

Dividendos de Iovance Biotherapeutics

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Forecast to breakeven in 2026

New minor risk - Financial position

Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi

Iovance Biotherapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Iovance Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Iovance Biotherapeutics, Inc. Agrees to A Proposed Settlement

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Consensus revenue estimates increase by 11%

Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer

New minor risk - Profitability

Iovance Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

New major risk - Share price stability

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Price target increased by 19% to US$24.42

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Consensus revenue estimates decrease by 25%

Iovance Biotherapeutics, Inc.’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

New minor risk - Profitability

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Iovance Biotherapeutics, Inc. Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

Price target decreased by 8.7% to US$20.42

Consensus revenue estimates decrease by 71%

Iovance Biotherapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Financial position

Independent Director recently bought US$27m worth of stock

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Updates

Price target decreased by 8.9% to US$22.36

Consensus revenue estimates decrease by 62%, EPS upgraded

New minor risk - Financial position

Iovance Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Shareholder dilution

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Price target increased by 13% to US$24.55

Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma

Consensus revenue estimates decrease by 21%, EPS upgraded

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Accepts the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Consensus revenue estimates increase by 1,282%, EPS downgraded

Consensus revenue estimates decrease by 84%, EPS upgraded

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited fo

Interim CEO exercised options and sold US$234k worth of stock

Chief Medical Officer exercised options and sold US$67k worth of stock

Price target decreased to US$23.00

Independent Director recently bought US$62k worth of stock

Independent Director recently bought US$65m worth of stock

Price target decreased to US$23.77

Independent Director recently bought US$62k worth of stock

Iovance Biotherapeutics, Inc. Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (Sitc) Annual Meeting

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iovance Biotherapeutics, Inc. Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte Therapy

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Independent Director exercised options to buy US$440k worth of stock.

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Price target decreased to US$25.17

Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss

Iovance: TIL Cell Therapy Set To Prove Itself

Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Dynamic Index

Iovance Biotherapeutics, Inc. Appoints Wendy L. Dixon to Board of Directors

Independent Director recently bought US$51k worth of stock

Price target decreased to US$30.77

Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma

Iovance: Onward To Approval

Iovance Biotherapeutics, Inc. Announces Regulatory and Clinical Updates for Lifileucel in Melanoma

Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside

Price target decreased to US$35.46

No longer forecast to breakeven